Table 2. The most common treatment-related adverse events.

	30 ( n =6)			40 ( n =3)			50 ( n =3)			60 ( n =3)			70 ( n =6)			Total ( n =21)
Dose (mg m−2 per day)	All	⩾G3	⩾G4	All	⩾G3	⩾G4	All	⩾G3	⩾G4	All	⩾G3	⩾G4	All	⩾G3	⩾G4	All (%)	⩾G3 (%)	⩾G4 (%)
Haematological toxicities
Leucopenia	4	1		2			2	1		3	1		6	4		17 (81.0)	7 (33.3)
Neutropenia	2		1	2			2	1		3	3		6	4		15 (71.4)	8 (38.1)	1 (4.8)
Red blood cell count decreased	2			2			3			2			5	1		14 (66.7)	2 (9.5)
Haematocrit decreased	3			2			3	1		2			4	1		14 (66.7)	1 (4.8)
Lymphocytopenia	3	1		1			3			2			4	3		13 (61.9)	4 (19.0)
Anaemia	4	1					2	2		2			4	4		12 (57.1)	7 (33.3)
Thrombocytopenia	2	1	1				1			1			5			9 (42.9)	1 (4.8)	1 (4.8)
Blood albumin level decreased				1			1			1			1			4 (19.0)
Blood bilirubin level increased				1						1			2			4 (19.0)
Aspartate aminotransferase level increased	1			1						1			1			4 (19.0)
Blood alkaline phosphatase level increased	1			1						1			1			4 (19.0)
Protein total decreased				1						1			1			3 (14.3)	1 (4.8)
Monocyte count increased	1	1											2			3 (14.3)
Alanine aminotransferase increased	1									1			1			3 (14.3)
Nonhaematological toxicities
Nausea	4						2			3			5			14 (66.7)
Appetite loss	5	1								3			5			13 (61.9)	1 (4.8)
Fatigue	3	1					2			1			2			8 (38.1)	1 (4.8)
Vomiting	2						1			2			1			6 (28.6)
Diarrhoea	1						2	1		1			1			5 (23.8)	1 (4.8)
Albuminuria	1			1						2			1			5 (23.8)
Stomatitis				1						1			1			3 (14.3)
Weight loss							1						2			3 (14.3)
Bloating	2						1									3 (14.3)